Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q1 2025 · 56 positions · Total reported value $926.70M · Top-10 concentration 58.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2025 13F filing, Eversept Partners, LP disclosed 56 equity positions with a combined reported value of $926.70M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 58.3% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were NTRA ($126.38M), GSK ($101.62M), HCA ($52.70M). By sector, the heaviest allocations are Health Care 81.6%, Industrials 5.9%. Versus the prior quarter, allocation shifted toward Health Care (+8.6pp) and away from Other (-8.8pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q1 2025 were NBIX ($18.50M), GKOS ($15.64M), GMED ($14.12M).

Of the 27 positions fully exited versus the prior quarter, the largest were VTRS ($15.84M), TLT ($15.67M), EW ($12.64M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • NBIX NEUROCRINE BIOSCIENCES INC · $18.50M
  • GKOS GLAUKOS CORP · $15.64M
  • GMED GLOBUS MED INC · $14.12M
  • ALGN ALIGN TECHNOLOGY INC · $7.83M
  • MOH MOLINA HEALTHCARE INC · $7.82M
  • NVAX NOVAVAX INC · $2.34M
  • ETNB 89BIO INC · $2.21M
  • MRVI MARAVAI LIFESCIENCES HLDGS I · $2.08M

Fully Exited (vs previous quarter)

  • VTRS Viatris Inc · prev qtr: $15.84M
  • TLT ISHARES TR · prev qtr: $15.67M
  • EW EDWARDS LIFESCIENCES CORP · prev qtr: $12.64M
  • DXCM DEXCOM INC · prev qtr: $11.56M
  • GH GUARDANT HEALTH INC · prev qtr: $8.43M
  • AZN ASTRAZENECA PLC · prev qtr: $6.73M
  • MEDP MEDPACE HLDGS INC · prev qtr: $6.33M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $6.10M · history

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 81.6%
Financials 0.1%
Other 9.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 893.72K $126.38M 13.64%
13.64%
Add
2 2.62M $101.62M 10.97%
10.97%
Reduce
3 152.50K $52.70M 5.69%
5.69%
Reduce
4 4.21M $51.75M 5.58%
5.58%
Add
5 1.90M $45.61M 4.92%
4.92%
Add
6 76.90K $43.02M 4.64%
4.64%
Add
7 299.09K $31.64M 3.42%
3.42%
Reduce
8 351.98K $31.10M 3.36%
3.36%
Reduce
9 186.43K $29.69M 3.20%
3.20%
Reduce
10 547.12K $26.46M 2.85%
2.85%
Reduce
11 8.46M $22.84M 2.46%
2.46%
Add
12 2.08M $22.46M 2.42%
2.42%
Hold
13 1.41M $21.68M 2.34%
2.34%
Reduce
14 557.07K $21.03M 2.27%
2.27%
Add
15 499.21K $20.84M 2.25%
2.25%
Add
16 340.34K $20.66M 2.23%
2.23%
Add
17 1.38M $18.57M 2.00%
2.00%
Add
18 167.24K $18.50M 2.00%
2.00%
New
19 57.49K $17.72M 1.91%
1.91%
Add
20 280.12K $16.42M 1.77%
1.77%
Reduce
21 2.17M $16.29M 1.76%
1.76%
Add
22 158.96K $15.64M 1.69%
1.69%
New
23 517.02K $15.60M 1.68%
1.68%
Add
24 816.25K $14.63M 1.58%
1.58%
Add
25 192.89K $14.12M 1.52%
1.52%
New
26 696.50K $12.64M 1.36%
1.36%
Reduce
27 24.00K $11.26M 1.22%
1.22%
Reduce
28 49.28K $7.83M 0.84%
0.84%
New
29 56.63K $7.83M 0.84%
0.84%
Reduce
30 23.73K $7.82M 0.84%
0.84%
New
31 27.97K $7.40M 0.80%
0.80%
Add
32 15.70K $6.83M 0.74%
0.74%
Reduce
33 280.95K $5.75M 0.62%
0.62%
Add
34 3.90M $4.29M 0.46%
0.46%
Reduce
35 445.59K $3.52M 0.38%
0.38%
Add
36 697.71K $3.51M 0.38%
0.38%
Reduce
37 70.33K $2.96M 0.32%
0.32%
Add
38 18.45K $2.35M 0.25%
0.25%
Reduce
39 365.52K $2.34M 0.25%
0.25%
New
40 150.48K $2.22M 0.24%
0.24%
Reduce
41 293.27K $2.21M 0.24%
0.24%
Reduce
42 303.73K $2.21M 0.24%
0.24%
New
43 942.45K $2.08M 0.23%
0.23%
New
44 122.82K $1.99M 0.21%
0.21%
Reduce
45 10.84K $1.90M 0.20%
0.20%
Reduce
46 1.68M $1.71M 0.18%
0.18%
Add
47 3.40M $1.52M 0.16%
0.16%
Add
48 2.29M $1.49M 0.16%
0.16%
Add
49 220.20K $1.31M 0.14%
0.14%
Hold
50 257.15K $961.76K 0.10%
0.10%
Reduce

FAQ

What did Eversept Partners, LP buy in 2025-Q1?

In its 2025-Q1 13F filing, Eversept Partners, LP reported 56 equity positions worth $926.70M in aggregate; its largest disclosed positions were NTRA ($126.38M), GSK ($101.62M), HCA ($52.70M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $926.70M of long equity holdings across 56 positions as of 2025-Q1. Top-10 holdings account for 58.3% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →